VetSheet

브로모크립틴

Bromocriptine

Bromocriptine mesylate

도파민 작용제 / 프로락틴 억제제POIMSC개고양이말

다른 이름: Parlodel · Cycloset · bromocryptine · 2-bromergocryptine · bromocriptine methanesulphonate · bromocriptini mesilas · 2-bromo-alpha-ergocryptine mesylate · 2bromoergocryptine monomethanesulfonate · CB-154

VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료

감사 완료 v13 용량 근거

구조화 용량 계산 근거

Pseudocyesis (pseudopregnancy) | suppression of lactation (extra-label)

10 mcg/kgPO
  • q8-12h

NA

반드시 함께 고려할 임상 맥락 (2)
  • ■ Vomiting, fatigue, and low blood pressure are possible. For dogs and cats, giving this medicine with food may help to decrease vomiting.
  • Protect tablets and capsules from light and store them in tight containers at 20°C to 25°C (68°F-77°F).
formulary프로토콜 2023감사 dose-audit-plumb-v13

용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.

진료 중이신가요? VetSheet의 AI가 약물, 용량, 투여 기간을 구조화된 진료 기록에 바로 기입합니다.VetSheet 작동 방식 보기

개요

브로모크립틴은 반합성 맥각 알칼로이드 유도체로 ​도파민 작용제​ 및 ​프로락틴 억제제​로 작용합니다.

  • ​개​: 임신 중절 또는 상상임신에 사용됩니다(위장관 부작용이 적은 카베르골린이 더 선호됨).
  • ​고양이​: 인슐린 요구량을 줄이기 위해 말단비대증의 보조 치료제로 간혹 사용됩니다.
  • ​말​: 역사적으로 뇌하수체 중엽 기능 장애(PPID/말 쿠싱 증후군) 또는 뇌하수체 선종에 사용되었으나, 현재는 페르골리드가 표준 치료제입니다.

​임상 요점​: 브로모크립틴은 개에서 심각한 구토를 유발하는 것으로 악명이 높으며, 이로 인해 임상적 유용성이 제한됩니다. 음식과 함께 투여하거나 항구토제 사용이 필요할 수 있습니다.

작용 기전

Bromocriptine acts primarily by stimulating postsynaptic dopamine (D2) receptors in the hypothalamus and anterior pituitary gland.

  • Prolactin Inhibition: Dopamine receptor stimulation → release of prolactin-inhibitory factor (PIF) → direct inhibition of prolactin secretion from the anterior pituitary.
  • Acromegaly: In certain pituitary adenomas, paradoxical suppression of growth hormone (GH) secretion occurs via dopaminergic stimulation.
  • CNS Effects: Activates dopaminergic receptors in the neostriatum of the brain, which can influence motor control and behavior.

안전성·주의사항

금기사항

  • Hypertension
  • Pregnancy (in humans, documented teratogenicity not established but contraindicated)
  • Nursing/lactating animals (interferes with lactation)

부작용

  • Nausea
  • Vomiting (highly prevalent in dogs)
  • Sedation
  • Fatigue
  • Hypotension
  • Anorexia
  • Depression
  • Trembling
  • Diarrhea
  • Tachycardia

주의

Bromocriptine is generally contraindicated in patients with hypertension. It should be used with caution in patients with hepatic disease as metabolism of the drug may be reduced. Do not use in nursing animals as it interferes with lactation.

약물 상호작용

Alcohol

May cause a disulfiram-type reaction

Butyrophenones (e.g., haloperidol, azaperone)

May increase prolactin concentrations; bromocriptine doses may need to be increased

Amitriptyline

May increase prolactin concentrations; bromocriptine doses may need to be increased

Phenothiazines

May increase prolactin concentrations; bromocriptine doses may need to be increased

Reserpine

May increase prolactin concentrations; bromocriptine doses may need to be increased

Cyclosporine

May elevate cyclosporine levels

Erythromycin

May increase bromocriptine levels

Clarithromycin

May increase bromocriptine levels

Estrogens or Progestins

May interfere with the effects of bromocriptine

Ergot Alkaloids

Not recommended; concurrent use has caused severe hypertension and myocardial infarction in humans

Hypotensive Medications

May cause additive hypotension

MAO Inhibitors (including amitraz, selegiline)

Avoid use of bromocriptine with these compounds

Metoclopramide

May cause prolactin release in dogs, negating the effects of bromocriptine for treating pseudopregnancy

Octreotide

May increase bromocriptine levels

Sympathomimetics (e.g., phenylpropanolamine)

Enhanced bromocriptine effects reported in humans (rare), including ventricular tachycardia and cardiac dysfunction

모니터링

  • Clinical efficacy (dependent upon the reason for use)
  • Blood pressure (especially if patients exhibit clinical signs associated with hypotension)

약동학

흡수

In humans, only about 28% of a bromocriptine dose is absorbed from the gut. Due to a high first-pass effect, only about 6% reaches the systemic circulation.

분포

Distribution characteristics are not well described, but in humans, it is highly bound (90-96%) to serum albumin.

대사

Metabolized by the liver to inactive and non-toxic metabolites.

배설

Eliminated primarily as metabolites.

과다투여

Overdosage may cause vomiting, severe nausea, and profound hypotension.

  • Clinical Signs in Dogs: Common findings recorded in decreasing frequency include vomiting, trembling, diarrhea, subdued behavior, and tachycardia.
  • Treatment: Standardized gut removal techniques should be employed when applicable, though emesis often occurs spontaneously. Institute cardiovascular monitoring (blood pressure, heart rate) and provide supportive care as needed.

제품

제형

  • Oral capsules
  • Oral tablets
  • Compounded injections (from oral dosage forms)

인용의약품

  • Bromocriptine Mesylate Oral Capsules: 5 mg (as base); Parlodel® (Novartis); generic
  • Bromocriptine Mesylate Oral Tablets: 0.8 mg (as base); Cycloset® (Patheon); 2.5 mg; Parlodel® SnapTabs (Novartis); generic

규제 현황

규제 데이터 없음: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

보관·안정성

Tablets and capsules should be protected from light and stored in tight containers at temperatures less than 25°C.

보호자 정보

  • ​음식과 함께 투여​: 식사와 함께 이 약을 투여하면 위장 장애와 구토의 가능성을 크게 줄일 수 있습니다.
  • ​메스꺼움 관찰​: 구토와 식욕 부진은 특히 개에서 매우 흔한 부작용입니다. 증상이 심하면 수의사에게 연락하십시오.
  • ​무기력​: 반려동물이 평소보다 피곤해하거나 진정된 것처럼 보일 수 있습니다.
  • ​수유 중인 반려동물에게 사용 금지​: 이 약은 모유 분비를 중단시킵니다.

​참고​: 반려동물이 쓰러지거나, 극도로 약해 보이거나, 심한 구토를 하는 경우 위험한 저혈압을 의미할 수 있으므로 즉시 수의사의 진료를 받으십시오.

VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.